CENTUM ELECTRONICS LIMITED

Disclosure pursuant to Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

[Pursuant to Regulation 14 read with Part F of Schedule I of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and Section 62(1)(b) of the Companies Act, 2013 read with Rule 12(9) of the Companies (Share Capital and Debentures) Rules, 2014]

SEBI vide its notification dated August 13, 2021 had issued the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations 2021 ('SEBI Regulations').

The disclosures pursuant to Regulation 14 of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations 2021 for ESOP 2013 Plan and RSU 2021 are as follows:

| SI | Particulars | ESOP 2013 | RSU 2021 |
|-----|--|---|---|
| No. | | | |
| A | Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of section 133 of the Companies Act, 2013 (18 of 2013) including the 'Guidance note on accounting for employee share-based payments' issued in that regard from time to time | Refer Note No. 47 forming part of the standalone financial statements for the financial year 2021-22. | No options have been granted under this Scheme during F Y 2021-22 |
| В | Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by Central Government or any other relevant accounting standards as issued from time to time | Refer Note 47 forming part of the standalone financial statements for the financial year 2021-22. | " |
| С | Details related to ESOS/RSU | | |
| i | A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including | | |
| (a) | Date of shareholders' approval: | 7th August, 2013 | 5 th October, 2021 |

| (b) | Total number of options approved under ESOS: | The maximum aggregate number of Shares that may be subject to Options and granted under the Plan is 2,50,000 Equity Shares. | The total number of RSUs granted shall not exceed 1,75,000 Equity Shares. |
|-----|--|--|---|
| (c) | Vesting requirements: | 25% on completion of one year from the date of grant of option. 25% on completion of two years from the date of grant of option. 25% on completion of three years from the date of grant of option. 25% on completion of four years from the date of grant of option. | No options have been granted under this Scheme during FY 2021-22. |
| (d) | Exercise price or pricing formula: | The price payable for exercising the Option under the Plan as may be decided by the Nomination and Remuneration Committee on the basis of the Market Price of the Shares. | 66 |
| (e) | Maximum term of options granted: | The equity shares covered under these options vest over a period ranging from twelve to forty eight months from the date of grant. The exercise period is ten years from the date of vesting. | " |
| (f) | Source of shares (primary, secondary or combination): | Primary | " |
| (g) | Variation in terms of options: | No variation was made in the terms of options during the financial year 2021-22 | " |
| ii | Method used to account for ESOS - Intrinsic or fair value | Fair Value | " |
| iii | Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be | Not Applicable | " |

| | | <u></u> | |
|-----|-----------------------------------|----------------|---|
| | disclosed. The impact of this | | |
| | difference on profits and on EPS | | |
| | of the company shall also be | | |
| | disclosed. | | |
| iv | Option movement during the | | |
| | year (For each ESOS) | | |
| | Number of options outstanding at | 19,026 | " |
| | the beginning of the period | | |
| | Number of options granted | - | " |
| | during the year | | |
| | Number of options forfeited / | 7,000 | " |
| | lapsed during the year | . , | |
| | Number of options vested during | _ | " |
| | the year | | |
| | Number of options exercised | | |
| | during the year | _ | |
| | Number of shares arising as a | | |
| | result of exercise of options | - | |
| | Money realized by exercise of | | |
| | | - | |
| | options (INR), if scheme is | | |
| | implemented directly by the | | |
| | company | NT_4 A1!. 1 1 | |
| | Loan repaid by the Trust during | Not Applicable | |
| | the year from exercise price | | |
| | received | 12.026 | |
| | Number of options outstanding at | 12,026 | " |
| | the end of the year | 40.55 | |
| | Number of options exercisable at | 12,026 | " |
| | the end of the year | | |
| V | Weighted-average exercise | Rs.71.25 | " |
| | prices and weighted-average fair | | |
| | values of options shall be | | |
| | disclosed separately for options | | |
| | whose exercise price either | | |
| | equals or exceeds or is less than | | |
| | the market price of the stock | | |
| vi | Employee wise details (name of | NIL | |
| | employee, designation, number | | |
| | of options granted during the | | |
| | year, exercise price) of options | | |
| | granted to | | |
| (a) | Senior managerial personnel as | NIL | " |
| (4) | defined under Regulation 16(d) | 1,112 | |
| | of the Securities and Exchange | | |
| | Board of India (Listing | | |
| | Obligations and Disclosure | | |
| | Congations and Discrosure | | |

| | Requirements) Regulations, 2015 | | |
|-----|--|---|---|
| (b) | any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year; and | NIL | " |
| (c) | identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant. | NIL | 6 |
| vii | A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information: | | " |
| (a) | the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model; | Refer Note 47 forming part of the standalone financial statements for the financial year 2021-22. | " |
| (b) | the method used and the assumptions made to incorporate the effects of expected early exercise; | " | " |
| (c) | how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and | | " |
| (d) | whether and how any other features of the options granted were incorporated into the measurement of fair value, such as a market condition. | | " |